Annual Report 2024

CONSOLIDATED STATEMENT OF CASH FLOWS For the year ended 31 December 2024 50 The United Laboratories International Holdings Limited Annual Report 2024 2024 2023 RMB’000 RMB’000 Investing activities Payments for purchase of property, plant and equipment (1,431,869) (1,144,206) Payment for deposits of acquisition of property, plant and equipment (283,298) (130,278) Proceeds on disposal of property, plant and equipment 9,514 4,367 Placement of pledged bank deposits (4,827,996) (3,626,330) Withdrawal of pledged bank deposits 4,765,879 3,348,785 Placement of financial asset at fair value through profit or loss (20,818,787) (2,365,774) Receipts of financial asset at fair value through profit or loss 20,885,788 2,438,522 Interest received 127,791 105,415 Additions to right-of-use assets (60,386) (136,383) Additions to intangible assets (94,727) (51,068) Net cash used in investing activities (1,728,091) (1,556,950) Financing activities Interest paid (68,398) (78,431) Dividends paid (1,017,535) (581,448) Capital contribution from the non-controlling interest of a subsidiary 36,000 12,000 Repayments of lease liabilities (5,266) (4,177) New borrowings raised 2,227,570 2,044,000 Repayments of borrowings (586,140) (2,778,755) Net settlement of foreign currency forwards 47,254 24,133 Payment on repurchase of shares (36,465) – Transaction costs attributable to repurchase of shares (112) – Net cash from (used in) financing activities 596,908 (1,362,678) Net increase (decrease) in cash and cash equivalents 2,068,119 (480,190) Effect of foreign exchange rate changes (267) (892) Total cash and cash equivalents at beginning of the year 4,261,989 4,743,071 Total cash and cash equivalents at end of the year 6,329,841 4,261,989